March 2019, Volume 5, Issue 4

March 2019

Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.

Table of Contents

March 2019 Issue

Book Review: Nine Pints of Liquid Gold

Friday, March 1st, 2019
ASH Clinical News Editor-in-Chief Mikkael A. Sekeres, MD, MS, reviews Nine Pints, an account of the science, politics, and social history of blood. Have you...

An Ode to Joy

Friday, March 1st, 2019
We have new leadership at my institution, who, in an act of inspiration (or accidental greatness), have declared that bringing joy back to the...

March 2019 Issue

Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...

Friday, March 1st, 2019
Weill Cornell Researchers Awarded $9 Million for Lymphoma Research The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...

ASH Recommends Changes to Continuing Board Certification, and more

Friday, March 1st, 2019
ASH Recommends Changes to Continuing Board Certification In December 2018, a commission appointed by the American Board of Medical Specialties (ABMS) and other entities released...

March 2019 Issue

Planes, Trains, and VTEs

Friday, March 1st, 2019
Simple recommendations can help mitigate risk for travel-related blood clots In November 2011, hematologist Suely Rezende, MD, PhD, deplaned from a flight from Lisbon to...

Pulling Back the Curtain: Dan Pollyea, MD, MS

Friday, March 1st, 2019
In this edition, Dan Pollyea, MD, MS, talks about his early experiences as a “physician’s assistant” and how he learned to talk to patients....

March 2019 Issue

The significance of JAK2-positive test results in a healthy patient

Friday, March 1st, 2019
This month Josef Prchal, MD, discusses the significance of JAK2-positive test results in a healthy patient. And don't forget to check out next month's clinical dilemma...

How I Treat In Brief: Treating the Young Patient With Multiple Myeloma

Friday, March 1st, 2019
Recently, Sara Gandolfi, MD; Claudia Paba Prada, MD; and Paul G. Richardson, MD, discussed the treatment of younger patients with multiple myeloma, balancing disease...

Reader Responses: The significance of JAK2-positive test results in a healthy patient

Friday, March 1st, 2019
Here’s how readers responded to a You Make the Call question about the significance of JAK2-positive test results in a healthy patient. Disclaimer: ASH does not...

March 2019 Issue

Dasatinib Granted Approval for Pediatric Indication

Friday, March 1st, 2019
The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...

Bristol-Myers Squibb to Purchase Celgene

Friday, March 1st, 2019
Bristol-Myers Squibb (BMS) agreed to buy Celgene for $74 billion, making it the second-biggest purchase in the pharmaceutical and biotechnology industry and continuing a...

ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma

Friday, March 1st, 2019
Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...
WIB_icon

Evaluating Midostaurin Plus Intensive Chemotherapy in Older Patients With AML

Friday, March 1st, 2019
Midostaurin plus intensive chemotherapy, followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent midostaurin maintenance therapy, was improved survival outcomes in patients with newly...

FDA Updates Guidance on Rare Disease Drug Development

Friday, March 1st, 2019
The U.S. Food and Drug Administration (FDA) released a revised draft guidance for sponsors developing “orphan drugs” for the treatment or prevention of rare...

Congress Passes Bipartisan Sickle Cell Bill

Friday, March 1st, 2019
The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...

Tagraxofusp-erzs Becomes First Approval for BPDCN

Friday, March 1st, 2019
The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

FDA Approves Ravulizumab for PNH

Friday, March 1st, 2019
The U.S. Food and Drug Administration (FDA) approved ravulizumab, a long-acting complement inhibitor that prevents hemolysis, for the treatment of adults with paroxysmal nocturnal...
WIB_icon

Ibrutinib and Palbociclib: A New Combination for Mantle Cell Lymphoma?

Friday, March 1st, 2019
The combination of ibrutinib and the CDK-4/6 inhibitor palbociclib could be safely administered to patients with previously treated mantle cell lymphoma (MCL), according to...

Caplacizumab Improves Platelet Normalization Time, Reduces Mortality in Acquired TTP

Friday, March 1st, 2019
Adding caplacizumab to standard of care for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) shortened the time to the normalization of platelet counts...

SHARE